Get the Stockscreener App
23.72
3.22%
0.74
After Hours:
24.12
0.40
+1.69%
Bicara Therapeutics Inc stock is traded at $23.72, with a volume of 736.82K.
It is up +3.22% in the last 24 hours and up +23.61% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
See More
Previous Close:
$22.98
Open:
$22.98
24h Volume:
736.82K
Relative Volume:
1.36
Market Cap:
$1.55B
Revenue:
-
Net Income/Loss:
$-137.95M
P/E Ratio:
-9.403
EPS:
-2.5226
Net Cash Flow:
$-107.11M
1W Performance:
+9.76%
1M Performance:
+23.61%
6M Performance:
+26.10%
1Y Performance:
+107.16%
1-Day Range:
$22.54
$24.00
1-Week Range:
$21.08
$24.00
52-Week Range:
$7.80
$24.00
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
617-468-4219
Address
116 HUNTINGTON AVENUE SUITE 703, BOSTON
Compare BCAX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAX
Bicara Therapeutics Inc
|
23.72 | 1.50B | 0 | -137.95M | -107.11M | -2.5226 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bicara Therapeutics Inc Stock (BCAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-26 | Initiated | BofA Securities | Buy |
| Jan-29-26 | Initiated | Citizens JMP | Mkt Perform |
| Jan-08-26 | Initiated | BTIG Research | Buy |
| Dec-18-25 | Initiated | Mizuho | Neutral |
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| May-23-25 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Apr-17-25 | Initiated | Wells Fargo | Underweight |
| Feb-06-25 | Initiated | Wedbush | Outperform |
| Dec-06-24 | Initiated | H.C. Wainwright | Buy |
| Nov-05-24 | Initiated | Rodman & Renshaw | Buy |
| Oct-08-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-08-24 | Initiated | Morgan Stanley | Overweight |
| Oct-08-24 | Initiated | Stifel | Buy |
| Oct-08-24 | Initiated | TD Cowen | Buy |
View All
Bicara Therapeutics Inc Stock (BCAX) Latest News
History Review: Is Bicara Therapeutics Incs growth already priced inOptions Play & Technical Buy Zone Confirmation - baoquankhu1.vn
CEO Moves: How liquid is Bicara Therapeutics Inc stockWeekly Risk Report & Free Reliable Trade Execution Plans - baoquankhu1.vn
BCAX PE Ratio & Valuation, Is BCAX Overvalued - Intellectia AI
Published on: 2026-04-10 20:40:14 - baoquankhu1.vn
Trading Recap: How is Bicara Therapeutics Inc managing supply chain issues2026 Retail & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Bicara Therapeutics stock hits 52-week high at 21.99 USD By Investing.com - Investing.com India
Bicara Therapeutics stock hits 52-week high at 21.99 USD - Investing.com
T. Rowe Price lists 10.1% of Bicara Therapeutics (NASDAQ: BCAX) in 13G/A - Stock Titan
Bicara Therapeutics Inc. (BCAX) stock price, news, quote and history - Yahoo Finance UK
Wall Street Analysts Believe Bicara Therapeutics Inc. (BCAX) Could Rally 54.85%: Here's is How to Trade - MSN
Bicara Therapeutics (NASDAQ:BCAX) Sets New 12-Month HighHere's Why - MarketBeat
A Look At Bicara Therapeutics (BCAX) Valuation After Earnings Losses And New Shelf Registration - Yahoo Finance
Bicara Therapeutics’ Earnings Call Highlights Pivotal Pivot - TipRanks
JonesTrading Maintains Bicara Therapeutics(BCAX.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Bicara Therapeutics CEO Sold Over 8,000 Company Shares. Is the Stock a Sell or Buy? - AOL.com
BCAX Technical Analysis & Stock Price Forecast - Intellectia AI
A Look At Bicara Therapeutics (BCAX) Valuation After Analyst Upgrades And Clinical Progress News - Sahm
Bicara Therapeutics Inc. (BCAX) Stock Price Prediction: Today, Tomorrow, Next Week - Traders Union
Bicara Therapeutics (BCAX) Is Up 13.5% After Breakthrough Status And Equity Raise Strengthen Cash Runway – Has The Bull Case Changed? - simplywall.st
Bicara Therapeutics Announces Inducement Grant - National Today
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Bicara Therapeutics Inc. common stock (NASDAQ:BCAX) Q4 2025 earnings call transcript - MSN
HC Wainwright Has Bullish Estimate for BCAX Q1 Earnings - MarketBeat
Bicara Therapeutics stock hits 52-week high, reaching $20.42 By Investing.com - Investing.com South Africa
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year? - qz.com
Wall Street experts predict that Bicara Therapeutics Inc. (BCAX) has the potential to surge by 54.85%: Strategies for Trading - Bitget
Is CareCloud (CCLD) Performing Better Than Other Medical Stocks This Year? - Bitget
Bicara Therapeutics (NASDAQ:BCAX) Hits New 1-Year High Following Analyst Upgrade - MarketBeat
Bicara Therapeutics stock hits 52-week high, reaching $20.42 - Investing.com
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), Bicara Therapeutics Inc. (BCAX) and Compass Therapeutics (CMPX) - The Globe and Mail
Bicara Therapeutics to rally around 121%? Here are 10 top analyst forecasts for Tuesday - MSN
Bicara: Maintaining 'Buy' Rating On Ficerafusp Alfa Phase 3 Advancement (NASDAQ:BCAX) - Seeking Alpha
BCAX SEC FilingsBicara Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at The Goldman Sachs Group - MarketBeat
Wells Fargo Maintains Rating on BCAX, Increases Price Target to - GuruFocus
Bicara Therapeutics (NASDAQ:BCAX) Given "Outperform" Rating at Wedbush - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Price Target Raised to $16.00 at Wells Fargo & Company - MarketBeat
Citizens Jmp Reiterates "Market Outperform" Rating for Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
BCAX Receives Updated Price Target from HC Wainwright & Co. | BC - GuruFocus
Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
HC Wainwright Increases Bicara Therapeutics (NASDAQ:BCAX) Price Target to $42.00 - MarketBeat
Bicara Therapeutics Inc. Common Stock Q4 2025 Earnings Call Summary - Yahoo Finance
H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress - Investing.com UK
H.C. Wainwright raises Bicara Therapeutics stock price target on trial progress By Investing.com - Investing.com South Africa
Citizens reiterates Bicara Therapeutics stock rating on trial progress By Investing.com - Investing.com Canada
Citizens reiterates Bicara Therapeutics stock rating on trial progress - Investing.com UK
Bicara Therapeutics Inc Stock (BCAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Bicara Therapeutics Inc Stock (BCAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Raben David | Chief Medical Officer |
Mar 25 '26 |
Sale |
18.95 |
5,500 |
104,229 |
55,286 |
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):